drugset / Trial / NCT04054414
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute spinal cord injury.
Timeline
- Start
- 2019-01-10
- Primary completion
- 2026-06
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SOVATELITIDE | Peptide | 0.3 ug/kg | Intravenous |